Qube Research & Technologies (QRT)’s Aclaris Therapeutics ACRS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-194,510	Closed	-$729K	–	3414
2026 Q1	$729K	Sell	194,510 -252,665	-57%	-$853K	﹤0.01%	2622
2025 Q4	$1.35M	Sell	447,175 -97,585	-18%	-$247K	﹤0.01%	2431
2025 Q3	$1.04M	Buy	544,760 +35,410	+7%	+$61.7K	﹤0.01%	2496
2025 Q2	$723K	Sell	509,350 -841,470	-62%	-$1.14M	﹤0.01%	2575
2025 Q1	$2.07M	Buy	1,350,820 +735,737	+120%	+$1.57M	﹤0.01%	1942
2024 Q4	$1.53M	Buy	615,083 +322,238	+110%	+$802K	﹤0.01%	1989
2024 Q3	$337K	Sell	292,845 -647,907	-69%	-$795K	﹤0.01%	2392
2024 Q2	$1.03M	Sell	940,752 -271,508	-22%	-$319K	﹤0.01%	1873
2024 Q1	$1.5M	Sell	1,212,260 -467,645	-28%	-$558K	﹤0.01%	1912
2023 Q4	$1.76M	Buy	+1,679,905	New	+$5.13M	﹤0.01%	1589
2021 Q1	–	Sell	-16,992	Closed	-$110K	–	1866
2020 Q4	$110K	Buy	+16,992	New	+$71.7K	﹤0.01%	1631

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ACRS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 194,510 shares — an estimated $729K sold.

Qube Research & Technologies (QRT) first reported a position in ACRS in Q4 2020 and held it in 11 quarters. The position peaked at $2.07M in Q1 2025. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Qube Research & Technologies (QRT) reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 194,510 Aclaris Therapeutics shares in Q2 2026, an estimated $729K.
Qube Research & Technologies (QRT) first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 11 quarters.
Qube Research & Technologies (QRT)'s Aclaris Therapeutics position peaked at $2.07M in Q1 2025.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.